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Natural selection shapes protein solubility to physiological requirements and recombinant
applications that require higher protein concentrations are often problematic. This raises the
question whether the solubility of natural protein sequences can be improved. We here show
an anti-correlation between the number of aggregation prone regions (APRs) in a protein
sequence and its solubility, suggesting that mutational suppression of APRs provides a simple
strategy to increase protein solubility. We show that mutations at specific positions within a
protein structure can act as APR suppressors without affecting protein stability. These
hot spots for protein solubility are both structure and sequence dependent but can be
computationally predicted. We demonstrate this by reducing the aggregation of human
a-galactosidase and protective antigen of Bacillus anthracis through mutation. Our
results indicate that many proteins possess hot spots allowing to adapt protein solubility
independently of structure and function.
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T
o function proteins have to fold into their native structure
while avoiding misfolding and aggregates. However, the
spread in cellular abundance of proteins in a typical
proteome spans about nine to ten orders of magnitude1. As
protein aggregation is a concentration-dependent process the
challenge posed to protein folding therefore varies enormously
between low- and high-abundant proteins2. Recent evidence
indicates the aggregation propensity of proteins is tuned to their
cellular abundance3,4 and that cellular protein levels correlate
with protein solubility5. This suggests protein solubility is on
average only marginally superior to physiological expression
levels and that many proteins are ‘living on the edge’6.
This has important implications for the production and use
of recombinant proteins in biotechnology and therapeutics.
Recombinant protein applications require protein concentrations
several orders of magnitude above natural abundance. As a result
several potentially valuable therapeutic proteins remain beyond
reach. This also raises fundamental questions on the evolutionary
mechanisms allowing adapting protein solubility to changing
requirements in protein abundance. Indeed, reducing the
aggregation propensity of globular proteins is not a straight-
forward task. Globular structure requires a hydrophobic core to
lock secondary structure elements into a well defined three-
dimensional fold, which in turn generates aggregation prone
amino acid sequences7,8. Protein structure and protein
aggregation are therefore entangled properties, rendering it very
difficult to remove protein aggregation without affecting protein
stability and structure9. The question therefore remains how
natural selection manages to co-evolve protein function and
solubility without affecting the native structure of proteins and by
extension, what we can learn from this to improve the properties
of industrial and therapeutic recombinant proteins.
Protein aggregation is a process resulting in the accumulation
of misfolded proteins into insoluble agglomerates. Although
hydrophobicity is often an important driver for phase separation
of misfolded proteins, structural aggregation itself is geared by
more specific interactions between identical linear aggregation
prone sequence regions (APRs) within the primary sequence that
assemble by intermolecular b-strand interactions. The determin-
ing role of APRs in protein aggregation has been demonstrated
for several amyloid-disease proteins by grafting experiments:
insertion of APRs from various proteins in a non-aggregating
scaffold domain results in similar aggregation propensity and
morphology than the original protein from which the APR was
derived10–12. On average a globular protein domain contains 2–4
APRs and B20% of the total protein sequence of any given
proteome is part of APRs13,14. It was demonstrated on a large set
of Escherichia coli proteins that the intrinsic aggregation
propensity of folded proteins correlates with their solubility15.
We show the solubility of proteins can directly be related to the
number of APRs within a protein sequence and that modulating
the number of APRs by mutation significantly affects protein
solubility. Moreover, we perform an analysis of the relationship
between protein structure and the aggregation propensity of its
primary sequence over a representative set of 584 high quality
crystal structures (R-factor o0.19 and resolutiono1.5 Å)
(ref. 16), representing all common protein folds. We find that
although most residues within APRs are in a structural gridlock
coupling aggregation and thermodynamic stability, specific
positions in a protein structure can be mutated to lower the
aggregation propensity of the primary sequence without
significantly affecting protein stability. These context-dependent
hotspots for solubility therefore allow to significantly improve
protein solubility in a step-wise manner by point mutations that
suppress individual APRs. These findings further clarify our
understanding of the selective pressures relating protein structure,
function and solubility. It confirms that although APRs cannot be
avoided altogether in globular proteins, protein aggregation is
under selective pressure. Our structural analysis demonstrates
this selective pressure is not saturated but dictated by
physiological requirements in protein abundance and as a result
most proteins have potential for increased solubility. We illustrate
these principles with two examples in which we introduced
mutations in these structural hotspots thereby increasing
resistance to protein aggregation without affecting structure or
function: a-galactosidase, a protein currently used in replacement
therapy for Fabry’s disease and the anthrax protective antigen, a
key component for recombinant anthrax vaccines.
Results
Protein abundance correlates with aggregation prone regions.
We used TANGO to predict all APRs in the E. coli proteome and
matched these (1) to E. coli protein solubility (3,173 proteins) as
measured by Niwa et al.17 using in vitro translation and (2) to
cellular abundance (597 proteins) data obtained by Vogel et al.18
using mass spectrometry (Supplementary Fig. 1A). We find a
good correlation (cor¼  0.96) between the number of APRs
and the protein solubility averaged by APR count. (Fig. 1a),
consistent with the notion that the burden of additional APRs
lowers the solubility of proteins. There is a large variation per
category (Supplementary Fig. 1B), indicating the effect of APRs is
modulated strongly by cellular and structural context. To ensure
the correlation is robust, we performed a bootstrap analysis, in
which we recalculated the same correlation based on 1,000
randomly selected samples, each consisting of 80% of the original
data points. The bootstrapped correlations are consistently
high (Supplementary Fig. 1C), supporting the robustness of the
observation. Similarly, we find a good correlation (cor¼  0.77)
between the number of APRs in a protein sequence and cellular
abundance (Fig. 1b). Again, there is quite some variation per
category (Supplementary Fig. 1D), but the correlation is robust in
1,000-fold bootstrap analysis (Supplementary Fig. 1E). It was
previously shown that protein solubility in vitro and cellular
protein abundance in vivo correlate, indicating that protein
solubility is tuned to their cellular abundance5,7. Our results
therefore suggest that altering the number of APRs would have a
strong effect on protein solubility and abundance. Interestingly,
the correlation between intrinsic aggregation propensity and
protein abundance improves when a higher TANGO cutoff is
employed (cor¼  0.97), although with a reduced number of
datapoints in the plot (Supplementary Fig. 1F), Nevertheless,
this suggests that the stronger APRs are relevant for protein
abundance in vivo, while all regions contribute to solubility
in vitro.
Protein sequences possess cryptic APRs. The existence of APRs
is a consequence of globular structure and especially of the
requirement of hydrophobic cores. At the same time it hampers
protein folding and limits protein solubility. Not surprisingly it
was found that APRs are subjected to negative selection19. The
most efficient strategy to eliminate APRs consists in mutating a
central hydrophobic residue in the APR to a charged residue or a
Pro, as these so-called aggregation gatekeepers disfavour the
b-structure adopted by hydrophobic sequences in aggregates20.
However, in practice in most cases it is impossible to place
charged residues at central positions within the APR without
obliterating the native structure given that APRs are often part of
the hydrophobic core. The next best solution to reduce
aggregation is to place gatekeepers at the flanks of APRs
(Fig. 1c) as these positions are relatively more solvent exposed
allowing to accommodate charges with an acceptable cost to the
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Figure 1 | APRs and gatekeepers in natural polypeptide sequences. (a) The scatterplot of the average experimentally determined solubility5,17 of E. coli
proteins grouped by the number of APRs in their sequence displays an anti-correlation, showing that on average protein solubility decreases with increasing
number of aggregation prone sequences. (b) A similar plot to A, but now for protein abundance in E. coli in vivo 5,17. Although the anti-correlation is weaker,
the trend suggests that cellular abundance is also limited by the number of APRs in its sequence. (c) Schematic representation depicting the TANGO profile
of a typical naturally occurring polypeptide stretch of 100 amino acids, containing two APRs (red) each flanked by an N-terminal as well as a C-terminal
gatekeeper (green), as well as one suppressed APR (blue) controlled by a single suppressing gatekeeper. (d) A density plot of the TANGO scores in the set
of 634 structurally diverse proteins (red), showing a strong bias towards lower scores. In the absence of gatekeeper residues, this distribution is biased
towards higher scores (green). The TANGO scores of the suppressed APRs (blue) show a more even distribution including higher scoring regions.
(e) Density plot showing the number of APRs occurring per 100 amino acids in 634 structurally diverse proteins (red line). The blue line shows the number
of ‘suppressed APRs’, which are not detected by TANGO in the WT sequence, but show up after mutation of a single Asp, Glu, Lys, Arg or Pro residue to
Ala. If mutation of such a residue reveals an APR that is undetectable in the WTsequence, we call that residue a ‘suppressing gatekeeper’. The inset shows
the frequency of the amino acid type of suppressing gatekeepers. (f) Density plot of the contribution of gatekeeper residues to the overall thermodynamic
stability of the native state of the protein as calculated by FoldX (red). The same plot for the suppressing gatekeepers in the same proteins (blue) is very
similar.
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thermodynamic stability of the protein21. Although this does
generally not allow to completely suppress protein aggregation,
the almost systematic placement of charges at the flanks of APRs
clearly minimizes aggregation as can be observed from the
exponential distribution of APR strength in the human proteome
(Fig. 1d) with the majority of APRs displaying low-to-moderate
aggregation tendencies. The green curve in the plot shows that
this distribution in the absence of the gatekeeper residues is
shifted towards much stronger aggregation propensities.
This general situation does not imply that it is necessarily
always impossible to silence an APR by placement of a central
gatekeeper. In fact the selective pressure against aggregation
suggests that proteins should possess a significant amount of
suppressed APRs (Fig. 1c). To investigate the existence of
suppressed APRs we analysed a non-redundant set (sequence
identity below 30%) of 584 proteins for which high quality crystal
structures were available (R-factor better than 0.19, resolution
better than 1.5 Å), which were previously selected by the
WHATIF consortium22. First, we used the TANGO software13
to identify all APRs and GKs in these proteins. However when a
gatekeeper residue is most effective, it will result in a sequence
that no longer scores as aggregation prone and hence, these
‘suppressing gatekeepers’ (sGKs) are not identified during the
standard analysis because the APR will not be detected (it is
suppressed). When such a residue is mutated to an amino acid
that does not oppose aggregation, the aggregation score for the
comprising region will dramatically increase, thus revealing the
suppressed APR (Fig. 1c). Of course, unequivocally identifying
suppressed APRs in this manner is impossible as we cannot make
the difference between a previously existent APR that has been
suppressed or a non-aggregating sequence that evolved one
mutation away towards aggregation for other functional reasons.
What this analysis can provide, however, is an idea of the number
of cryptic APRs in a protein sequence and thus the number of
positions within a sequence that are hotspots for susceptibility to
aggregation upon mutation.
To identify sGKs we truncated all Arg, Lys, Glu, Asp and Pro
residues outside of already identified APRs individually to Ala
and employed TANGO to identify those residues whose
truncation to Ala leads to the detection of a novel APR in the
mutated sequence. The APR discovered in this way we call
‘cryptic APR’ and the residue that keeps its aggregation
propensity low in the wild-type (WT) sequence ‘suppressing
GK’. It should be noted that the choice for mutating to Ala is
guided by the structural considerations under study, that is, the
interdependence of protein aggregation and stability. This
conservative mutation is a good reporter both for aggregation
(its aggregation propensity is a good approximation for the
average of all amino acids) and for the thermodynamic
contribution of that residue to the structure (mutation to Ala
removes interactions without introducing new ones).
This analysis revealed that on average for every two regular
APRs, proteins contain another cryptic APR and that 40% of
proteins in this set have no sAPR, whereas this is less than 5% for
real APRs (Fig. 1e) suggesting that indeed it is structurally more
difficult to silence an APR by sGK than to cap the flanks of APRs
with GK. The frequency of each of the five amino acid types of
gatekeepers is roughly equal (Fig. 1e, inset) and in contrast to
regular APRs, whose intrinsic aggregation propensity is strongly
biased to the lowest TANGO scores, the cryptic APRs have
TANGO scores across the entire spectrum (Fig. 1d). Taken
together, these data suggest that any gatekeeper residue can be
employed to silence the intrinsic aggregation propensity of an
APR, and the limitation to its placement will come predominantly
from compatibility with the folded structure. In order to evaluate
this, we employed the FoldX algorithm23 to quantify the
contribution of individuals GKs and sGKs to protein stability,
which yielded similar distributions largely centred around zero
(Fig. 1f). Importantly, the FoldX analysis suggests that B40% of
GKs and sGKs come at a thermodynamic cost to the stability of
the native structure, suggesting that the net gain for minimizing
aggregation often outweigh the price paid in terms of
thermodynamic stability.
sGK mutations are enriched in disease mutants. To further
evaluate the importance of sGKs we analysed the frequency of
loss of sGKs through mutation in the Varibench set of 19,335
disease mutations and 21,170 human non synonymous coding
single-nucleotide polymorphisms. This revealed that the loss of a
sGK is twice as likely in the disease set than in the
polymorphism set (Fig. 2a, inset), suggesting that this type of
mutation is likely to be deleterious, consistent with the notion
that sGKs fulfil an important role in repressing cryptic APRs. In
addition, we analysed PaxDB24, an integrated database for the
natural abundance of human proteins, comparing the abundances
of proteins that contain disease-associated and neutral mutations
that affect sGKs (Fig. 2a). Statistical analysis shows these
distributions differ significantly (Mann–Whitney U-test P value
of 5.43 10 11), suggesting that mutation of a sGK in a highly
abundant protein is more likely to be disease-associated than in a
lowly abundant protein. This underlines the importance of this
novel class of residues in polypeptide sequences.
Decreasing aggregation without affecting structure. The overall
selective tendency to minimize the aggregation propensity in a
proteome by flanking gatekeepers or suppressing gatekeepers
does not mean that all APRs are necessarily optimized to
saturation point. This idea is compatible with the observation that
protein solubility is generally optimized to its physiological
abundance but generally not more4,5. The question therefore
remains to what degree the aggregation of natural protein
sequences is still amenable to improvement.
To investigate this, we systematically mutated every residue
that is part of an APR in the same set of 634 proteins individually
to Pro, Arg, Lys, Asp and Glu and recorded the predicted change
in aggregation propensity (TANGO) and protein stability (DDG).
Figure 2b shows a density distribution of the resulting 75,720
mutations as a heat map from yellow (frequent) to red (rare),
revealing as expected that for most positions in the protein
sequence mutations improving the aggregation propensity of the
sequence do so at a major cost for thermodynamic stability
(values of 5 kcalmol 1are unlikely to occur in an experimental
setting and result from strong Van der Waals clash penalties in
FoldX). However, some density can be observed in the
region of the plot corresponding to a strong reduction of
intrinsic aggregation at a low cost to thermodynamic stability
(o1 kcalmol 1), suggesting that additional gatekeepers at
selected positions is structurally possible. As is shown in
Fig. 2c, in about half the protein domains at least one such
gatekeeper could be placed in silico, suggesting there is significant
potential for protein improvement at specific sites within protein
structures.
To validate these principles, we experimentally investigated
the effect of introducing artificial gatekeeper mutations in two
example proteins: the human protein a-galactosidase and
protective antigen (PA) from Bacillus anthracis.
Rational design of aggregation-resistant a-galactosidase.
Human a-galactosidase (a-Gal) is a lysosomal hydrolase. a-Gal
deficiency results in Fabry disease (FD) (OMIM 301500), a
metabolic X-linked inherited lysosomal storage disorder25,26.
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a-Galactosidase enzyme replacement therapy is currently used to
treat FD. The structure of a-galactosidase consists of a
homodimer, in which each monomer contains a (b/a) domain
(Fig. 3a, central part, yellow and green parts) harbouring the
active site and an antiparallel b-domain (Fig. 3a, orange and
blue). The APRs of a-Gal (indicated with 1, 2 and 3 and coloured
in red in Fig. 3b, upper left), cluster in the b-domain and the
interface between the domains. From visual inspection of the
structure, region 3 in particular is likely to be at risk of nucleating
aggregation, given its edge position in the b-sheet. The results of
the computational gatekeeper scan of each of the APRs of a-Gal
are shown as a MASS-plot (mutant aggregation and stability
spectrum), that is, a scatter plot (Fig. 3c) of the change in
thermodynamic stability (DDG values calculated by FoldX in
kcalmol 1) versus change in the intrinsic aggregation propensity
(values calculated by TANGO, range between 0 and 100 per
amino acid residue) associated to each APR. These plots allow to
easily identify ideal mutations with large negative values on both
axes, that is, mutations that reduce the intrinsic aggregation
propensity while not decreasing the thermodynamic stability
of an APR. Confirming our bioinformatics analysis above,
designable positions in a-Gal exist but are sparse and context-
dependent. For example, for APR1, no improving mutations
could be identified, owing mainly to its complete burial inside the
tightly packed domain interface. APRs 2 and 3 display one
favourable mutation each (A348R and A368P, respectively), with
an additional mutation in APR3 (A368R) stabilizing the region
without lowering intrinsic aggregation (Fig. 3c).
In addition, to further reduce aggregation we also looked for
mutations that stabilize the b-domain of the protein. Even though
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Figure 2 | Potential for introducing artificial gatekeepers. (a) Comparison of the frequency of mutations that remove suppressing gakekeepers (sGKs) in
pathogenic mutations and polymorphisms. The overall frequency is shown in the inset, whereas the main plot shows how the frequency of these mutations
varies according to the cellular abundance of the WT proteins, showing that removal of a sGK is more likely to be neutral in proteins that occur at a low
cellular concentration. (b) A systematic mutational scan of all residues of 4,730 APRs in 634 structurally diverse proteins. Each residue was mutated to Pro,
Arg, Lys, Asp or Glu and its effect on intrinsic aggregation propensity and protein stability (DDG) estimated using TANGO and FoldX, respectively. Heat
map analysis (red to yellow gradient indicating increasing density) of the change in intrinsic aggregation propensity versus protein stability (DDG) shows
that the main density of mutations occurs at a high cost to thermodynamic stability and with moderate reductions of intrinsic aggregation and that only a
minority of mutants significantly reduce aggregation without affecting thermodynamic stability (green box). (c) Density plot of the number of artificial
gatekeepers within the green box of b that reduce significantly the aggregation propensity of an APR without affecting thermodynamic stability of the native
structure (DTANGOo 250 and DDG-value o1 kcalmol 1).
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these do not reduce APRs, the additional thermodynamic stability
will minimize the detrimental effect of introducing artificial
gatekeepers at other sites. An exhaustive in silico mutation scan
throughout the b-domain yielded a set of mutations increasing
thermodynamic stability (Table 1). The most stabilizing mutation
(S405L, DDGFoldX¼  3.34 kcalmol 1) tightens the interaction
of the edge b-strand (the site of APR3) with the rest of the
domain. We experimentally verified the effect of all mutations,
comparing them with WT a-Gal and D165V and A288D, FD
mutants previously found to be particularly aggregation prone27.
Mutants were transiently overexpressed in HeLa cells and a-Gal
solubility was measured in lysates by western blotting of size
exclusion chromatography (SEC) elution fractions (material and
methods). WT protein elutes mainly as a dimer but also shows
faint bands in the SEC fractions eluting at volumes corresponding
to large molecular sizes (Fig. 4a) (exclusion limit of this column is
600 kDa), consistent with partial misfolding and aggregation of
WT a-Gal. As expected, the disease associated mutations D165V
and A288D display significant increase of these high molecular
weight fractions at the expense of the dimer fraction. The
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Figure 3 | Structure and aggregation propensity of human WT a-Gal. (a) Human a-Gal is a homodimer (PDB 3GXP)54 in which each monomer
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structure was visualized with YASARA (ref. 53). (b) The intrinsic aggregation propensity of the a-Gal sequence as predicted by the TANGO algorithm
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Table 1 | Mutations with predicted beneficial effect on
thermodynamic stability 42 kcalml 1 obtained by FoldX
analysis.
pos wt mut difTANGO difstab
405 S L 0,03  3,34
405 S M 0,02  3,09
333 Q R 1,8  2,62
368 A P  91,8  2,31
408 N P 0,1  2,27
327 Q M 0,0  2,20
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individual mutations selected to reduce aggregation show a
modest decrease in the high molecular weight fractions when
compared with WT a-Gal, that is most pronounced for the
A348R mutant (Fig. 4a and Supplementary Fig. 2). Quantification
of the solubility confirmed that while aggregating mutants
(D165V and A288D) were highly insoluble (o10% of total
protein), our single-point mutants reached B80–90% solubility
compared withB70% for WT (Fig. 4b). We also determined the
enzymatic activity of lysates of HEK293 cells transiently
expressing a-Gal by following the conversion of the fluorogenic
substrate 4-methylumbelliferyl-a-D-galactopyranoside (4-MU-a-
Gal) over time. Single-point mutants showed similar enzymatic
activity in comparison to WT (Fig. 4c), suggesting these
mutations did not affect the active site of the enzyme and did
not interfere with its enzymatic function. Overall, the effects of
the single mutants are rather modest but show a decrease of
aggregation and an improved solubility while leaving enzymatic
activity unharmed. The fact that the observed improvements are
overall modest is explained by the fact that a-Gal possesses three
APRs: improving one by a single mutation leaves it susceptible to
aggregation by the other regions. It is therefore expected that
targeting several zones in parallel by multiple mutants should
have a synergistic effect on the solubility of a-Gal.
To determine the best combinations of mutations, we
generated several double (A348R/A368P and A348R/A368R)
and triple mutants (A348R/A368P/S405L and A348R/A368R/
S405L) consisting of the single mutations in APRs 2and 3 and the
stabilizing mutant S405L. First, we observed no significant
changes in the intrinsic enzymatic activity of the mutants
compared with WT (Fig. 5a) upon transient expression, showing
our mutations had no major effects on the catalytic site. A similar
level of soluble enzyme is reached (Fig. 5b) for WT and mutants,
but there is a clear reduction of fraction of the mutants in the
insoluble fraction by western blot (Fig. 5b and Supplementary
Fig. 3). Moreover, this is mirrored by reduced accumulation of
soluble aggregates for the mutants by SEC analysis (Fig. 5c and
Supplementary Fig. 4). Together these data show the rational
redesign of APRs in a-Gal is able to generate double and triple
mutants that optimize protein solubility by reducing protein
aggregation.
Rational design of aggregation-resistant PA. Protective antigen
(PA) is an element of the protein toxin secreted by B. anthracis28.
It is a key component of recombinant Anthrax vaccines, since the
immune response against this virulence factor confers protection
against B. anthracis infection29. However, recombinantly PA
(rPA) stored in aqueous solution is aggregation-prone30,31. The
structure of PA reveals four domains32. Domain 1 (Fig. 6a, grey)
contains two calcium-binding sites and the furin cleavage site
required for proteolytic activation of the molecule. Domain 2
(Fig. 6a, red) is required for membrane insertion and together
with domain 3 (Fig. 6a, yellow) for heptamer formation. Domain
4 (Fig. 6a, purple) is essential for binding cell surface
receptors28,32. TANGO detects several APRs in the amino acid
sequence of the protein (Fig. 6b). It was experimentally
demonstrated that the solvent exposed APR (APR1, Fig. 6a,b)
in domain 3 is the key determinant of rPA aggregation in vitro33.
Therefore, even though analysis suggests improvements are
possible for all three APRs, we focused on APR1 (Fig. 6a,b,
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N573IYTVLD579). The MASS plot identified position Thr576 as a
suitable design hot spot, allowing for mutation to Glu, Lys and
Arg. WT and three mutant proteins were recombinantly
expressed in E. coli and purified (see methods). The
hydrodynamic radius of the proteins was measured using
dynamic light scattering (DLS) before and after heat stress
(Fig. 7a), revealing a clear increase in the size of WT, consistent
with aggregation. Mutants showed a mild (T576R) to strong
(T576E and T576K) resistance to size increase upon heat stress
suggesting lower aggregation. To corroborate this observation we
analysed the T576E mutation in more detail by synthesizing the
corresponding WT and mutant APR1 (NATNIYTVLDKIK and
NATNIYEVLDKIK) as peptides. Analysis of secondary structure
of these peptides by Fourier transform infrared spectroscopy
(FTIR) (Fig. 7b) reveals the WT peptide displays an amide I band
near 1,620 cm 1, consistent with aggregation, while the mutant
peptide displays a markedly different spectrum with a peak near
1,680 cm 1 consistent with a b-turn structure. An additional
in silico mutation screen using FoldX revealed the stability of
the T576E mutant could be improved by 1.2 kcalmol 1 by a
compensatory mutation S559L. The corresponding double
mutant protein was purified and subjected to heat stress
followed by native polyacrylamide gel electrophoresis (PAGE)
(Fig. 7c), revealing a clearly increased heat resistance compared
with the WT and a clear improvement over the single mutation.
Far and near UV circular dichroism spectroscopy (CD) (Fig. 7d)
and near UV confirmed conservation of the structure between
T576E/S559L and WT. Differential Scanning Calorimetry
(Fig. 7e) of WT and T576E/S559L revealed only a slight
increase in melting temperature Tm of the T576E/S559L
mutant (47.8±0.13 C) compared with the WT (46.4±0.13 C)
by 1.4 C (t-test P¼ 0.002), but the narrower transition for the
mutant is consistent with a more cooperative unfolding
transition. Moveover, whereas WT shows characteristic signals
of aggregation in the plot from 50 C upwards, the T576E/S559L
mutant starts aggregating only at a higher temperature,
suggesting we have removed the APR responsible for
aggregation during storage at room temperature. To further
corroborate this observation, we performed a temperature
ramped assay, in which we simultaneously measured changes in
intrinsic tryptophan fluorescence (ITF) and right-angle light
scattering (RALS)34,35, allowing the combined monitoring of
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unfolding (Tm, Supplementary Fig. 5A) and aggregation (Tagg,
Supplementary Fig. 5B) temperatures in function of a
temperature gradient of 0.3 Cmin 1. The Tm values obtained
by this method are similar to those observed by DSC
(46.76±0.24 C and 47.23±0.09 C for WT and T576E/S559L
mutant, respectively). The aggregation onset temperatures differ
by 2.4 C from 47.42±0.01 C for WT to 49.86±0.01 C for the
T576E/S559L mutant, again in good agreement with the DSC
data. Plotting aggregation versus degree of unfolding, it appears
the aggregation onset for WT occurs at 53% of the unfolding
transition, whereas for the mutant aggregation only initiates at
84% of the unfolding transition (Supplementary Fig. 5C). This is
consistent with our design, in which we reduced the aggregation
propensity of the strongest and most exposed APR by the T576E
mutation, delaying aggregation until more advanced denaturation
when the remaining APRs eventually become solvent exposed
and initiate aggregation. We also performed similar combined
ITF and RALS measurements under isothermal conditions at
40 C, where both WT and mutant are still on the native baseline
in the temperature ramp experiment but close to the unfolding
transition. During the first 2 h of this experiment, both mutant
and wild type equilibrated to a partially denatured conformation
at 38% of the unfolding transtion (Supplementary Fig. 5D). As
expected for an aggregation reaction, we observed a lag phase
during which the light scattering remains near the baseline,
followed by a rapid increase of scattering intensity (Fig. 7f and
Supplementary Fig. 5E). During this experiment the aggregation
of WT initiates betweenB2 h, whereas the T576E/S559L mutant
shows only marginal aggregation over 10 h, demonstrating an
increased stress resistance.
To further investigate the effect of the mutations on the protein
structure, we solved the crystal structure of the mutant by
molecular replacement (1acc (ref. 32)—Fig. 8a) to a resolution of
1.9 Å (Supplementary Table 1) leading to a model that had 0.78Å
rmsd for 675 superposed atoms (Fig. 8b), indicating our
mutations were highly conservative of the structure. The mutant
side chains were well defined in the electron density (Fig. 8c,d and
Supplementary Fig. 6) and superposed well with the predicted
side-chain conformations by FoldX (Fig. 8e,f), further validating
our approach.
a b
c
Domain 1
Domain 2
Domain 3
Domain 4
0
20
40
60
80
100
0 100 200 300 400 500 600 700 800
TA
N
G
O
 s
co
re
Residue number
1
2
3
–2
0
2
4
6
8
10
–400 –300 –200 –100 0 100
ΔΔ
G
 F
ol
dX
 (k
ca
lm
o
l–1
)
ΔTANGO
T576E
T576R T576K
–5
0
5
10
15
20
–180 –160 –140 –120 –100 –80 –60 –40 –20
ΔΔ
G
 F
ol
dX
 (k
ca
lm
o
l–1
)
ΔTANGO –5
0
5
10
15
20
–200 –150 –100 –50 0
ΔΔ
G
 F
ol
dX
 (k
ca
lm
o
l–1
)
ΔTANGO
2
1
3
Figure 6 | Structure and aggregation propensity of protective antigen (PA) of B. anthracis. (a) Monomeric PA is composed of four structural domains
consisting predominantly of anti-parallel b-sheet: D1 is the calcium-binding domain (grey), D2 is the membrane insertion and heptamerization domain
(red), D3 is the heptamerization domain (yellow) and D4 is the receptor binding domain (purple). (b) The intrinsic aggregation profile as predicted by
TANGO indicated the presence of three main APRs, which are located in domains 3 and 4. The aggregation kinetics were shown to be dominated by the
solvent exposed APR1 in the loop region of domain 3 (ref. 33). (c) MASS plots for the three APRs indicated in b. The mutations in APR 1 that we focused on
are indicated in red.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10816 ARTICLE
NATURE COMMUNICATIONS | 7:10816 | DOI: 10.1038/ncomms10816 |www.nature.com/naturecommunications 9
We verified the biological function of the protein as well as its
ability to raise a protective immune response upon injection
in mouse. To assay protein function, we treated Raw264.7
transformed mouse macrophage cells with T576E/S559L
mutant and WT rPA in combination with B. anthracis protein
lethal factor (LF) and determined the lethal dose required to kill
50% of the cells (LD50, Fig. 9a). The LD50 values for mutant and
WT were identical within error: 116.3±6.5 for WT and
111.6±3.4 for the mutant. However, repeating the assay after
increasing times of heat stress at 45 C, WT activity decreased
further than the mutant (Fig. 9b), leading to 20% residual activity
of WT after 1 h at 45 C compared with 80% for the mutant.
Finally, we carried out four repeat injection of mutant rPA in
mouse (days 0, 7, 10 and 18) and collected blood on day 28 to
determine the response titre by ELISA (Fig. 9c). The data show
that the naive animals have no anti-rPA antibodies and that
after the immunization there is a clear immune response to the
mutant and that the mutant antiserum recognizes WT and
mutant rPA to comparable level, showing the functionality of
mutant rPA as a vaccine component is also conserved. Taken
together, our data indicate that mutant T576E/S559L displays
a lower aggregation propensity than the WT protein, while
conservating both structure and biological activity of the PA
protein.
wt  R E LE 
a b
Aggregation 
Folded State Unfolding 
c d
e f
0
2 104
4 104
6 104
8 104
1 105
0 2 4 6 8 10 12 14 16
Sc
at
te
rin
g 
in
te
ns
ity
 a
t 4
73
 n
m
 (a
.u.
)
t (h)
60
50
40
30
20
10
0
WT E mut K mut R mut 1,700
190 200 210 220 230 240 250 260
12,000
8,000
4,000
–4,000
–8,000
–12,000
0
1,680 1,660 1,640 1,620 1,600
R
H
 
(nm
)
Cp
Ab
so
rb
an
ce
rPA
Wavelenght (nm)
Wavenumber (cm–1)
Mutant (turns)
Mutant
Mutant
Wild type (β-sheet)
Wild type
Wild type
Tempetature (°C)
[θ
] m
rw
 
(de
g c
m2
 
dm
ol
–
1 )
20 30 40 50 60
Figure 7 | Comparison of the aggregation behaviour of WT and mutant PA. (a) The hydrodynamic radius (RH) of WT and single Gk mutant PA before
(green bar) and after exposure (red bar) to thermal stress at 45 C for 30min. (b) Infrared amide I band of the WT (NATNIYTVLDKIK) and mutant
sequence (NATNIYEVLDKIK) surrounding the mutation site of PA APR 1. (c) Western blot of WT, single and double mutant PA before and after exposing to
thermal stress at 45 C for 30min. The lanes 1 and 2 of each sample represent the soluble fraction of PA under normal conditions (25 C) and after thermal
heat stress (40 C for 30min). (d) Far UV circular dichroism (CD) spectra of the WTand double-mutant (T576E/S559L) PA at 25 C. (e) DSC thermogram
of WT (red) and double-mutant (T576E/S559L) PA (green). (f) Static light scattering (SLS) at 473 nm measured over time for WT (red) and double-
mutant (T576E/S559L) (green) at 40 C.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10816
10 NATURE COMMUNICATIONS | 7:10816 | DOI: 10.1038/ncomms10816 | www.nature.com/naturecommunications
Discussion
Protein aggregation is one of the main limiting factors for the use
of proteins at concentrations far above those for which
evolutionary selection has shaped them. Indeed, the global
correlation between cellular abundance and protein solubility
strongly suggests proteins are operating near their solubility limit7.
It follows that use of a protein at higher-than-native
concentrations requires adaptation of its primary sequence, but
it is not immediately apparent how much scope for improvement
natural sequences harbour and how many mutations are required
for notable improvements. Moreover, the fact that protein
abundances are more conserved than mRNA levels could point
towards a solubility deadlock for many protein sequences36,
potentially restricting the scope for artificial protein improvement.
On the other hand, we now understand the basic mechanisms of
aggregation. Recently, several reports were made of mutationally
reducing protein aggregation through either rational design or
directed evolution37–43. The most successful of these mutations
involve the introduction of charged residues, which could be due to
the increase of the colloidal stability by augmenting the net charge
of the protein. On the other hand, these residues are also
reminiscent of aggregation gatekeepers. This class of residues was
discovered some time ago to flank nearly all naturally occurring
APRs44. These gatekeepers are usually charged amino acids and
Pro, although some reports also include His and Gly45.
Gatekeepers kinetically control aggregation sufficiently to favour
folding. Their placement at the flanks of APRs results from the fact
that APRs are usually part of an element of secondary structure in
the hydrophobic core of the protein, where charged or structure
breaking residues cannot be accommodated. Gatekeepers are
therefore enriched at the first possible polypeptide position
emerging from the hydrophobic core of the protein.
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Our current analysis suggests these earlier analyses may have
overlooked one of the most effective forms of aggregation
gatekeepers, namely those where placement in the centre of an
APR is possible, resulting in its complete suppression, thus
rendering it invisible to prediction algorithms. We termed these
residues suppressing gatekeepers and a survey of natural
polypeptide sequences identified about 1 of these sGKs in every
100 amino acids on average. We find that sGK are more
frequently mutated in disease-associated mutations than in
polymorphisms, suggesting they have strong impact on protein
solubility. However, protein folding and structure put many
restrictions on the mutations that can be introduced in a
polypeptide, and functional sites provide yet another level of
complexity. We were therefore intrigued to find that at least
in silico the potential for introducing additional suppressing
gatekeeper residues is not exhausted in natural sequences,
potentially providing a rational way to engineer more soluble
protein sequences through reduced aggregation. The crux is
finding the few sites where sGKs can be introduced without
violating structure. We followed this up for two examples: human
a-galactosidase and protective antigen from B. anthracis and
found that we could reduce aggregation by exploring a very small
number of mutations. In both cases, we found back charged
amino acids, making it difficult to distinguish effects resulting
from increased colloidal stability from those resulting from the
elimination of an aggregation prone region. Given that the
importance of the latter has been demonstrated in a range of
experiments, the effect of the artificial introduction of suppressing
gatekeepers is probably an integration of both effects in a single
mutation.
Since for the two examples analysed here we managed to
introduce residues reducing protein aggregation while conserving
both protein structure and function one might wonder why these
solutions have not been explored naturally. Of course, the
concentration at which these proteins naturally occur may be
below their critical concentration for aggregation or they may
benefit from chaperone interactions to such an extent that
aggregation is not a feature on which selection has to act. Still, it is
interesting to note that of all the mutations in a-Gal and rPA that
we analysed here, only one (A368P) is a naturally accessible
variation, considering single codon changes of the nucleotide
sequence. This would imply that even if these proteins would be
under selective pressure to increase their solubility, at least this
particular set of solutions is not immediately accessible.
Methods
Plasmid construction and mutagenesis. The full-length cDNA sequence encoding
human a-Gal A (NM_000169) was cloned into the pcDNA4/TO/myc-His vector
(Invitrogen). The insert was amplified using primers specific for the human a-Gal
gene on Gene Pool cDNA template from human normal skeletal muscle (Invitrogen)
with Phusion polymerase (Finnzymes). Then, the PCR product was digested with
restriction enzymes Hind III and Xho I and cloned in pcDNA4/TO/myc-His vector
to generate an open reading frame encoding a-Gal with a C-terminal Myc-tag.
Expression vectors containing single, double and triple mutated a-Gal (D165V,
A288D, A346P, A368P, A368R and S405L) were generated by site-directed
mutagenesis using sequence-specific primers and PWO DNA polymerase (Roche).
The gene sequence coding for anthrax protective antigen was synthesized by
GenScript and subcloned into the bacterial expression vector pET22bþ . This
vector confers ampicillin resistance and includes the pelB sequence for periplasmic
expression. No affinity tag sequence was included. Mutants were made in house
using site-directed mutagenesis and mutation was confirmed by DNA sequencing.
Cell culture and transient transfection. Human cervical cancer cell line HeLa
and human osteosarcoma cell line U2OS (used for maximum 20 passages) were
cultured in DMEM/F12 medium (Gibco) supplemented with 10% FCS and 1%
antibiotics (penicillin/streptomycin) at 37 C in 5% CO2. For transient transfection
in six-well culture plates, 350.000 HeLa cells were plated per well in the medium
without antibiotics. An amount 1 mg of plasmid DNA was transfected into HeLa
cells using FuGENE HD transfection reagent (Roche) according to manufacturer’s
protocol. For transient transfection in 96-well culture plates, 6.000 HeLa and U2OS
cells were plated per well in the medium without antibiotics. An amount 0.1 mg of
plasmid DNA was transfected into the cells using FuGENE HD transfection
reagent (Roche) according to manufacturer’s protocol. Forty-eight hours after
transfection, cells were removed from the incubator and examined.
SDS–PAGE and western Blot. Forty-eight hours after transfection HeLa cells were
lysed in RIPA buffer (1% octylphenoxypolyethoxyethanol (IGEPAL), 0.5% sodium
deoxycholate and 0.1% SDS) (Pierce) supplemented with protease inhibitors
(Roche) and fractionated by SDS–PAGE (NuPAGE system, Invitrogen). For
Western blot the scraped cells were heated with 2% SDS buffer at 99 C for 10min,
separated using a 10% Bis-Tris gel in MES running buffer and subsequently
transferred by electroblotting (fixed current 0.4 A) on a nitrocellulose membrane
(Millipore). The membrane was incubated in 5% dried non-fat milk powder
dissolved in 0.2% Tris Buffer Saline-Tween (TBST) for 1 h at room temperature
and subsequently incubated with primary mouse anti-myc antibody (Invitrogen)
followed by incubation by secondary goat HRP-conjugated anti-mouse IgG
(Promega). Proteins were visualized using chemiluminescence immunoblotting
detection reagent (ECL, Millipore).
Size exclusion chromatography. For the analysis of the a-Gal aggregation state
using SEC, transfected HeLa cells were lysed in RIPA buffer supplemented with
protease inhibitors, centrifuged 5min at 3,000 r.p.m. and 400ml of the supernatant
was subsequently loaded onto a Superdex S200 HR10/30 column (GE Healthcare)
equilibrated in hypotonic buffer (20mM HEPES, 10mM KCl, 1mM MgCl2, 1mM
EDTA, 1mM EGTA, 1mM DTT and pH 7.5). Eluted fractions were concentrated
by 20% trichloroacetic acid precipitation, washed with acetone and analysed by
SDS–PAGE. The bands densities were quantified using the Quantity One program
from the ChemiDoc System (Bio-Rad). A mixture of molecular weight markers
(Bio-Rad) was injected onto the column as a gel filtration standard.
Enzymatic assay. The activity of a-Gal was determined by fluorogenic substrate
4-methylumbelliferyl-a-D-galactopyranoside (5mM 4-MU-a-Gal) as described
previously46. N-acetylgalactosamine (D-GalNAc) was used as an inhibitor of a-Gal
B activity. a-Gal B is a second a-Gal in the cells that hydrolyses the artificial
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substrate but its activity in FD patients is normal or increased. In brief, HeLa cells
transfected with WT or mutant a-Gal were harvested and lysed in PBS by three
cycles of freezing/thawing in acetone-dry ice water bath. The supernatant obtained
by centrifugation at 10,000g was incubated with substrate solution (5mM 4-MU-a-
Gal and 100mM D-GalNAc in 0.1M citrate buffer pH 4.5) at 37 C and the
fluorescence was measured in a plate reader (POLARstar OPTIMA, BMG Labtech)
within an hour. The slope of the linear part of the substrate conversion curve was a
measure of the concentration of active enzyme in the lysates. a-Gal concentration
in the whole-cell lysates was determined by Western blot. To determine the
enzymatic activity, the assays were performed in three independent experiments.
Protein crystallization and X-ray structure determination. APA S559L/T576E
protein solution was concentrated to 9.6mgml 1 and crystallization screens
were set up using a Mosquito nanoliter crystallization robot (TTP Labtech).
Plate-shaped crystals appeared within a couple of days and grew at 4 C to
4100mm in size within one week under the following conditions: 20mM MgCl2;
100mM HEPES pH 7.5; and 22% poly(acrylic acid sodium salt) 5,100. Crystals
were flash-cooled in liquid nitrogen after cryo-protection with 30% glycerol.
X-ray diffraction data were collected to a resolution of 1.94 Å at the X06A beam
line of the Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland). Full
crystallographic and refinement statistics are reported in Supplementary Table 1.
Diffraction data were processed with XDS47 and scaled with SCALA in the CCP4
suite48. The structure was solved using molecular replacement in PHASER using
the published APA structure32 (pdb accession code 1ACC) as a search model. The
obtained model was automatically rebuilt using Autobuild in the PHENIX suite49.
Iterative cycles of manual model building and refinement in COOT50 and PHENIX
were carried out until the R-factors converged to a value of 17.8% and 22.7%
(Rwork and Rfree, respectively). The higher resolution structure of the published
APA K446M structure51 (pdb accession code 4EE2) was used to guide rebuilding of
surface-exposed loops with poor electron density. The final model includes residues
S14-S163, T169-D276, R287-V303, V320-S339 and E343-G735. All omitted regions
correspond to surface-exposed loops that have poor electron density. Model
validation was done using MOLPROBITY52 and all figures were prepared using
PyMOL (Schro¨dinger).
Statistical analysis. To confirm the consistency of the results, all described
experiments were performed in minimum three separate replicates. For statistical
evaluation of the determined averages and standard deviations of the mean, data
were analysed for significant differences using unpaired Student’s t-test with a
P value o0.05 (Po0.05). Asterisks indicating the level of the P value centred over
the error bar mean: ‘*’ Po 0.05, ‘**’ Po 0.01, ‘***’ Po 0.001 and ‘****’ Po0.0001.
Bio-informatics analysis. TANGO13 was used to determine APRs in human
proteins. This resulted in an aggregation propensity (0–100%) for each residue,
whereby an aggregating segment is defined as a continuous stretch of at least five
consecutive residues, each with a TANGO score higher than 5%. As each APR has
an average TANGO score, ranging from 0 to 100, aggregating segments are binned
based on this average value. All modelling was performed using the FoldX 3b5.1
force field23 and tool suite and structural visualization was achieved using Yasara53.
Immunization. Polyclonal antibodies were raised in rat via a 28 days Speedy
Polyclonal Antibody program at Eurogentec. WT and mutant PA were prepared
for immunization as follows. Under sterile conditions alhydrogel aluminium
hydroxide gel adjuvant (Brenntag) (conc. 10mgml 1¼ 1%) was washed three
times in 9mM sodium phosphate pH 7.3, 137mM NaCl, 12mM KCl and finally
resuspended in this buffer at a concentration of 1%. Protein was filtered through a
100mm filter and the buffer exchanged to 9mM sodium phosphate pH 7.3,
137mM NaCl, 12mM KCl (also sterile filtered). Protein concentration was
calculated using a theoretical extinction coefficient of 80,200. Protein and adjuvant
were mixed by rotating at 4 C for one hour to a final concentration of 2.6mgml 1
(0.26%) adjuvant and 0.2mgml 1 PA protein, transferred to sterile glass vials and
sent to Eurogentec. Upon completion of the 28 days Speedy program Eurogentec
performed antiserum analysis by an indirect ELISA assay against WT PA to
compare pre-immune serum with immunized serum.
Protein expression. An amount 20 ml calcium competent BL21 (DE3) cells were
transformed with 10 ng plasmid DNA (WT or mutant), plated on LB-agar plus
100mgml 1 ampicillin, and incubated overnight at 37 C. The following day a
single colony was used to inoculate 10ml LB medium plus 100 mgml 1 ampicillin
and incubated overnight at 37 C, shaking. The next day this overnight culture was
used to inoculate 1,000ml of LB medium plus 100mgml 1 ampicillin. Cells were
grown at 37 C plus shaking until an OD of 0.4–0.6 was reached, at which point the
cultures were cooled to 25 C over a period of 1 h. Protein expression was induced
by the addition of 1mM IPTG and additional ampicillin was added at
100mgml 1. Protein expression was allowed to proceed overnight, cells were
harvested by centrifugation and bacterial cell pellets stored at  80 C before
protein purification.
Protein purification. Bacterial cell pellets were recovered from  80 C and
thawed on ice. Ice cold lysis buffer was added at a ratio of 50ml per 1,000ml of
bacterial culture pelleted and the combination gently stirred for 1 h at 4 C. Lysis
buffer; 50mM Tris-HCl pH 7.8, 1mM EDTA, 30mM Benzamidine HCl, plus the
necessary amount of protease inhibitor tablets (complete ultra, mini EDTA-free,
Roche); pH was adjusted to pH 7.8 and the buffer supplemented to 25% sucrose.
1mgml 1 lysozyme (from chicken egg white, Fluka) was added and Universal
Nuclease (Pierce) were also added at 1:10,000. Cell lysate was centrifuged at 32,800g
for 20min (4 C), and the supernatants collected. An equal volume of ice cold
20mM Hepes pH 7.0 was added and the samples were kept on ice. Supernatant was
subjected to anion exchange chromatography (HiTrap Q HP, 5ml, GE Healthcare)
which was equilibrated with five column volumes 20mM Hepes pH 7.0. Protein
was eluted with a 0–250mM NaCl gradient, anthrax protective antigen eluted at
80mM NaCl. Anthrax Protective Antigen was immediately diluted 1:1 with
ice-cold 2.5mM K2HPO4 and then applied to a hydroxyapatite column (CHT
Ceramic Hydroxyapetite, 5ml, Bio-Rad) equilibrated with 10 column volumes
2.5mM K2HPO4. Protein was eluted with a 2.5–250mM K2HPO4gradient,
anthrax protective antigen eluted at 5mM K2HPO4. Both chromatographies were
performed at 4 C. Protein was concentrated by centrifugation using a molecular
weight cutoff of 30,000Da, simultaneously exchanging the buffer to 1PBS, 0.02%
tween, 500mM sucrose. Protein was flash frozen in liquid nitrogen and stored
at  80 C
Lethal factor toxicity assay. Raw 264.7 cells were seeded at 30K cells/well in a
96-well plate and the following day a toxicity assay was performed as follows. WT
and mutant PA were diluted to 1mgml 1 in 1 PBS and samples were heated for
0, 5, 15, 30 and 60min in a 45 C heat block. Samples were incubated on ice and
immediately filtered through SpinX cellulose acetate filters (Sigma). An equal
volume was taken from all samples, based on the start concentration of 1mgml 1,
to achieve a dilution of 500 ng ml 1 in DMEM (plus 10% FCS and antibiotics)
containing 2,000 ngml 1 Anthrax Lethal Factor, Recombinant (Calbiochem
#176900) (LF). Medium was aspirated from the cells and protein/lethal factor
combinations were added at 100 ml per well. Controls for this assay were: (a) zero
PA zero LF; and (b) zero PA, 2,000 ng ml 1 LF, 50mg ml 1 Mellitin (Sigma,
M2272-1MG), medium alone (no cells). After an incubation period of 4 h at 37 C
toxicity was assayed using the CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (G3580, Promega) as per the manufactures instructions. In addition, the
supernatants of the heated samples were probed by Western blot. An amount of
2 ml of protein sample was subjected to SDS–PAGE using Bio-Rad any kD TGX
gels and transferred to nitrocellulose membrane using a Bio-Rad Turbo Blot
system. The membrane was blocked overnight with 1 PBS, 1% BSA,
0.05%Tween. Primary antibody (mouse mAb to PA (BAP0101) Abcam ab1988)
was diluted 1/2,000 diluted in blocking buffer and incubated for 1 h. The
membrane was washed 3 10min with 1PBS, 0.05% Tween. Secondary anti-
body (anti mouse HRP: W4021, Promega) was diluted 1/2,000 diluted in blocking
buffer and incubated for 1 h. The membrane was washed 3 10min with PBS
0.05% Tween and 1 10min with ultra pure water. Protein was visualized using
Immobilon Western Chemiluminescent HRP substrate (WBKLS0050, Millipore).
Biophysical characterization. DLS measurements were made at room tempera-
ture with a DynaPro DLS plate reader instrument (Wyatt, Santa Barbara, CA, USA)
equipped with a 830-nm laser source. Samples were placed into a flat-bottom
96-well microclear plate (Greiner, Frickenhausen, Germany). The autocorrelation
of scattered light intensity at a 90 angle was recorded for 10 s and averaged over 40
recordings to obtain a single data point. The Wyatt Dynamics software was used to
calculate the hydrodynamic radius by assuming a spherical particle shape.
Attenuated total reflection FTIR was performed using a Bruker Tensor 27 infrared
spectrophotometer equipped with a Bio-ATR II accessory. Spectra were recorded in
the range of 900–3,500 cm 1 at a spectral resolution of 4 cm 1 by accumulating
120 data acquisitions. The spectrophotometer was continuously purged with dried
air. Spectra were corrected for atmospheric interference, baseline-subtracted, and
rescaled in the amide II area (1,500 to 1,600 cm 1). Circular dichroism (CD)
spectra were recorded using a Jasco J-715 spectropolarimeter (Jasco, Easton, MD,
USA) equipped with a temperature-controlled cell holder thermostated at 25 C.
The far UV and near UV CD spectra of PA in PBS were recorded in a cylindrical
quartz cuvette (Hellma) of path length 0.01 and 0.5 cm, respectively. Each CD
spectra is an average of 5 scans recorded at a scan speed of 50 nmmin 1 (far UV)
and 20 nmmin 1 (near UV). The data was baseline corrected for buffer
absorption, smoothed using Savitzky-Golay algorithm and converted to mean
residual weight units. Tm and Tagg of were determined simultaneously using ITF
and RALS using the OPTIM 1000 (Unchained Labs, Boston, USA) instrument.
All experiments were performed in triplicates of triplicates. For the temperature
ramped experiments a linear ramp was done with a increase of 0.3 Cmin 1.
For the isothermal experiments a temperature of 40 C was maintained. Exposure
time was set to 1,000ms, slit width was 100mm. The barycentric mean and
scattering at 266 and 475 nm were calculated and plotted using R-studio.
DSC measurements. The thermal unfolding transition mid-point temperature
(Tm) of WT and mutant rPA was measured using a Micro-Cal VP DSC. A 0.516ml
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solution of WT or mutant rPA (0.5mgml 1) dissolved in 10mM PBS pH 7.4 was
loaded in the Micro-Cal sample cell and thermograms were recorded at a scan rate
of 1 Cmin 1 with PBS in the reference cell. Thermograms were analysed and
curve fitted using Micro-Cal Origin 7.0 software. The experiments were performed
in triplicates using freshly prepared rPA samples.
Agal fractionation. HeLa cells were cultured in DMEM medium supplemented
with 10% FBS, 1mM sodium pyruvate and non-essential amino acids. For transient
transfection in 6-well culture plates, 300,000 HeLa cells were plated per well and
1.5 mg of plasmid DNA was transfected into the cells using Lipofectamine 2,000
transfection reagent (Life technologies). Twenty-four hours after transfection, cells
were wash with cold PBS and lysed in buffer (1% octylphenoxypolyethoxyethanol
(IGEPAL), 0.1M Dithiothreitol (DTT) and 3mM NaCl in Tris pH 8) supple-
mented with protease inhibitors (Roche). Lysates were centrifuged for 15min at
13.400 r.p.m. at 4 C and the supernatant was separated from the pellet. The pellets
were washed with lysis buffer and dissolved in 8M urea for 1 h. For Western blot,
samples were boiled in sample buffer (2% SDS and 1% 2-Mercaptoethanol) for
10min, run on Any Kd gels (Biorad) and transferred to nitrocellulose membranes
(Biorad). The membranes were blocked for 1 h with 5% milk powder dissolved in
0.2% TBST, incubated with primary mouse anti-myc antibody (Life technologies,
46-0603) or primary mouse anti-GAPDH antibody (Santa Cruz, SC-32233),
followed by incubation with secondary goat HRP-conjugated anti-mouse antibody
(Promega). Proteins were visualized using chemiluminescence.
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